Indication intelligence, analysis and sector perception

Lower open expected; RegMed Investors’ pre-open, get some!

August 25, 2016 7:41am

… Time to get in the “sand box” with equity positions

Potential winners in this market favor oversold shares that are ripe for an upside signal

… After the past day’s depreciation

Companies in my headlights: AGTC, BLUE, CLLS, OPXA and XON

Futures and indexes are DOWN except the IBB (+0.19) which is UP

I answer one question; in which company should investors put, keep and commit their money!

Where is today’s market going?

Subscribe and find out!

Where do investors turn for insight and perspective - I say what others won't, so you can do what others can't!

Indexes and ETFs: The IBB (+0.19%) is UP and the IWM (-0.40) and XBI (-0.16) are DOWN while the the XLV is NOT indicating

the Dow futures are DOWN -0.20% and NASDAQ futures are DOWN -0.21%

U.S. stock index futures indicated a lower open on Thursday as traders eyed the release of data and anticipated Friday's speech from the U.S. Fed’s Yellen.

European stocks were posting sharp losses, dragged down by mining and healthcare stocks as investors trod cautiously ahead of a speech by the Fed’s that could provide hints on the timing of a U.S. interest rate hike.

Asian stocks were mixed, as traders stayed on the sidelines ahead of a speech from the U.S. Fed that analysts said could provide clues about the central bank's next move.

Data docket: Initial jobless claims and durable goods orders are set to come out at 8:30 a.m. ET, with Markit Services PMI due at 9:45 a.m.

The stem, cell, gene and regenerative therapy (SCG&RT) sector closed NEGATIVE on Wednesday and Tuesday, POSITIVE on Monday, NEGATIVE on Friday and POSITIVE last Thursday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

Wednesday closed NEGATIVE with 35 decliners, 5 advancers and 3 flats;
Tuesday closed NEGATIVE with 28 decliners, 14 advancers and 1 flat;
Monday closed POSITIVE with 14 decliners, 27 advancers and 2 flats;
Friday closed NEGATIVE with 29 decliners, 13 advancers and 1 flat;
Last Thursday closed POSITIVE with 14 decliners, 26 advancers and 3 flats;

Remembering Wednesday’s closing post, “Every sector and market needs a certain amount of speculative sentiment, or risk-taking. Seeing stem, cell, gene and regenerative therapy stocks “dance” all over the tape, in my mind, opens the door to a solid pricing spurt, but for how long? The health and breadth of the sector is “flagging” and can be disastrous; if it is seen as defeatist – put a line in the sand – it’s an opportunity for reward!”

The issue at hand is a risk-on mindset.

I’m still holding on to “some” equities, recommending BUYING others!

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?

Watch list:

The iShares Nasdaq Biotechnology (IBB) closed Wednesday down -3.36% and is UP +0.19% in Thursday’s pre-market;
The SPDR S&P Biotech ETF (XBI) closed Wednesday down -4.30% and is DOWN -0.16% in Thursday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) closed down Wednesday -1.60% and is NOT indicating in Thursday’s pre-market;
The iShares Russell 2000 (IWM) closed down -0.78% on Wednesday and is DOWN -0.40% in Thursday’s pre-market.

Companies in my headlights:

Applied Genetic Technologies (AGTC) closed DOWN -$1.05 to $13.58 after Tuesday’s $14.63 (-$0.19). It’s been a merry-go-round seven days of trading. The last time we saw a $13.00 close was June 28 at $13.43. I do have concerns that AGTC hasn’t reported financial results/earnings after Fidelity dumped their position and Biogen (BIIB) has been reviewing all internal programs and collaborations. Still, Oversold – BUY;

bluebird bio (BLUE) closed DOWN -$4.65 to $50.26. The last four day’s pricings are telling with Monday’s $54.91, Friday’s $53.73 and last Thursday’s $56.70 pricings. The aftermarket is positive +$0.17. Oversold – BUY;

Cellectis SA (CLLS) closed DOWN -$0.11 to $26.97 after Tuesday’s $27.08 (+$0.43). The aftermarket indication is positive +$0.79. I am reversing myself from yesterday but, remember the title – “potential winners in this markets favor shares that are ripe for an upside signal” – SELL to BUY;

Intrexon (XON) closed DOWN -$2.98 to $26.29. The past four days have not indicated the need for Florida municipalities to address the growing ZIKA menace – Monday’s $29.27, Friday’s $29.84 and last Thursday’s $29.35. The aftermarket indication is positive +$0.66. Oversold - BUY

Opexa (OPXA) closed DOWN -$0.18 to $4.51 flowing Tuesday’s $4.69 (+$0.26). It’s been a good five days post Monday’s $4.43, Friday’s $4.20, Thursday’s $4.27 and last Wednesday’s $4.16; however, OPXA has got more to fall to be ready for an appreciation conversion. Overbought and the chart looks “ripe” for more profit taking – Maintaining SELL;

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

6 hours 40 min ago
RMi pre-open: Green on the screen

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.